A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis

Paused · Not applicable

Conditions studied: Cystic Fibrosis

In brief

Long term use of bronchodilators in CF is beneficial to the improvement of pulmonary function and symptoms. This study is investigating the long-term benefit of administration of the drug Salmeterol, a bronchodilator. Salmeterol will be compared to albuterol or placebo. The medication will be inhaled twice a day for 6 months.

Key facts

Study ID

NCT00005110

Run by

National Center for Research Resources (NCRR)

Last updated by the study team

2005-06-24

Who can join

Age: 5 and older, up to 45. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to perform reproducible spirometry
• FEVI > 50% and < 90% (Knudsen)
• A CF pulmonary exacerbation within the last year or an FEVI<80%
• At least one delta f508 allele on CF mutation analysis
• Ability to demonstrate use of inhaled medicine and FEVI and PEFR monitor
• Written informed consent
• Negative serum pregnancy test on enrollment

Where it is running

• Division of Allergy and Pulmonary Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.